WO2000056326A1 - Utilisation de la vitamine c ou analogues pour promouvoir la transformation de procollagenes inactifs en collagenes actifs - Google Patents
Utilisation de la vitamine c ou analogues pour promouvoir la transformation de procollagenes inactifs en collagenes actifs Download PDFInfo
- Publication number
- WO2000056326A1 WO2000056326A1 PCT/FR2000/000562 FR0000562W WO0056326A1 WO 2000056326 A1 WO2000056326 A1 WO 2000056326A1 FR 0000562 W FR0000562 W FR 0000562W WO 0056326 A1 WO0056326 A1 WO 0056326A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ascorbic acid
- active
- iii
- skin
- insoluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to a method for transforming inactive types I and III procollagens into active types I and III collagen by applying to the skin a composition comprising an effective amount of ascorbic acid or of at least one of its analogs. .
- Human skin is made up of two compartments, namely a surface compartment, the epidermis, and a deep compartment, the dermis.
- the natural human epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with solid support. It is also its nourishing element. It mainly consists of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, known as the fundamental substance, components synthesized by the fibroblast. There are also leukocytes, mast cells or tissue macrophages. It is also crossed by blood vessels and nerve fibers. In normal skin, that is to say non-pathological or scarring, the fibroblast is in a quiescent state, that is to say non-proliferative, not very active from a metabolic point of view and not mobile.
- Collagen fibers which ensure the solidity of the dermis.
- Collagen fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures, collagen types I and III represent 90% of matrix collagen.
- the solidity of the dermis is largely due to the entanglement of collagen fibers packed against each other. others in every way. Collagen fibers participate in the elasticity and tone of the skin and / or mucous membranes.
- the synthesis of collagen fibers begins with the synthesis of mRNA procollagens of types I and III, followed by their translation into procollagens of types I and III, these procollagens undergo different stages post -translational to make them active (or effective). These procollagens are first hydroxylated on their praline and lysine residues by the lysine- and praline-hydroxylases. The inactive and soluble procollagens thus obtained carry amino- and carboxy-terminal propeptides allowing their transport at a distance from their place of synthesis towards the extraceliular matrix where they become insoluble and active by spontaneous polymerization after cleavage of these propeptides.
- N-PCP raminoprocollagen peptidase
- C-PCP carboxyprocollagen peptidase
- the collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis. It is also recognized that extrinsic factors such as ultraviolet rays, tobacco or certain treatments (glucocorticoids, vitamin D and derivatives for example) also have an effect on the skin and its collagen level.
- extrinsic factors such as ultraviolet rays, tobacco or certain treatments (glucocorticoids, vitamin D and derivatives for example) also have an effect on the skin and its collagen level.
- the main modifications concerning the dermis are a reduction in the collagen level and the dermal thickness. This leads in menopausal women to thinning of the skin and / or mucous membranes. The woman then feels a feeling of "dry skin” or of skin that pulls and there is an accentuation of fine wrinkles and fine lines on the surface. The skin has a rough appearance on palpation. Finally, the skin has reduced flexibility.
- One of the aims of the present invention is therefore to promote the transformation of inactive types I and III procollagens into active types I and III collagen.
- the Applicant has now discovered that the ascorbic acid applied topically to the skin promotes the transformation (a) of inactive and soluble types I and III procollagens into active and insoluble types I and III procollagens, and (b) of these the latter in active type I and III collagen, insoluble and stable.
- Ascorbic acid is known to stimulate the synthesis of collagen, by preventing, as a co-factor, the auto-inactivation of the enzymes lysine- and praline- hydroxylases and by increasing the synthesis of mRNA of procolla fauxs .
- Ascorbic acid (or vitamin C) is also known to stimulate the synthesis of elastin in the skin.
- US patents 5801192, US 4983382 and EP 0717983 We can also cite an article entitled "Pola to incorporate vitamin C in new cosmetics line for skin care" of the Japan economy Journal of June 5, 1984 (page 15) .
- ascorbic acid applied topically to the skin makes it possible to increase the synthesis of mRNA of enzymes aminoprocollagen peptidase (N-PCP) and carboxyprocollagen peptidase (C-PCP) and thereby increase the transformation of inactive and soluble type I and III procollagens into active and insoluble type I and III procollagens.
- N-PCP aminoprocollagen peptidase
- C-PCP carboxyprocollagen peptidase
- ascorbic acid applied topically to the skin increases the synthesis of lysyloxidase mRNA and thereby increases the transformation of active and insoluble types I and III procollagens into type I collagens and III active, insoluble and stable.
- Promoting the transformation of inactive types I and III procollagens into active types I and III collagens notably improves the appearance of the skin and more particularly reduces the signs of aging of the skin, in particular by improving elasticity, the tone or firmness of the skin or by reducing wrinkles or delaying their appearance.
- a subject of the invention is therefore the use of an effective amount of ascorbic acid or one of its analogs in a composition or in the preparation of a composition intended to be applied to the skin to increase the transformation of procollagens of types I and III inactive and soluble in procollagens of types I and III active and insoluble.
- a second object of the invention is the use of an effective amount of ascorbic acid or one of its analogs in a composition or in the preparation of a composition intended to be applied to the skin to increase the transformation of procollagens types I and III active and insoluble in collagen types I and III active, insoluble and stable.
- the analogues of ascorbic acid are, more particularly, its salts, such as in particular sodium ascorbate, magnesium or sodium ascorbylphosphate, its esters, such as in particular its acetic, propionic or palmitic esters, or its sugars , such as in particular glycosylated ascorbic acid.
- Ascorbic acid is usually in L-form because it is usually extracted from natural products.
- the effective amount of ascorbic acid or its analogs which can be used according to the invention is of course that which is necessary to obtain the expected effects according to the invention.
- this quantity preferably represents from 0.001% to 20% of the total weight of the composition, preferably from 0.1% to 15% of the total weight of the composition and advantageously from 3% to 10% of the total weight of composition.
- composition of the invention is used for a time sufficient to obtain the expected effects according to the invention.
- this duration can be at least 3 weeks, but can also be more than 4 weeks, or even more than 8 weeks.
- composition of the invention intended for topical application contains a physiologically acceptable medium, that is to say compatible with the skin including the scalp, mucous membranes and / or the eyes and may in particular constitute a cosmetic or dermatological composition. .
- This composition can be in all the galenical forms normally used in the cosmetic and dermatological fields, and it can in particular be in the form of an aqueous solution possibly gelled, of a dispersion of the lotion type possibly biphasic, of an emulsion obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of a triple emulsion (W / O / W or O / W / O) or of a vesicular type dispersion ionic and / or non-ionic.
- These compositions are prepared according to the usual methods.
- composition of the invention can constitute for example a lotion, a gel, a cream or a milk, and for example a lotion or a cleansing or cleansing milk, a shampoo or a shower gel.
- the following example illustrates the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight, unless otherwise stated.
- Citric acid 1 H2O 1, 24%
- Biopsies of these treated surfaces are then carried out. 2. Extraction and purification of total RNA.
- Biopsies are ground under liquid nitrogen in a Mikrodismembrator S (Braun).
- the powder obtained is collected in the teflon capsule with 2 ml of lysis solution (guanidine isothiocyanate 5M, mercaptoethanol, 0.1 M, laurylsucosyl of Na 0.017M, citrate Na 0.025M, pH7, antifoam 3 ⁇ l / ml).
- the suspension is transferred to a tube, stirred at room temperature for 15 minutes.
- the lysate is deposited on the surface of a 1.4 ml cushion of 5.7M cesium chloride, 0.1 M EDTA, pH 7 in a 3.8 ml polyallomer tube for the rotor SW60 (Beckman L70M ultracentrifuge ). A 35,000 RPM uitracentrifugation is carried out for 18 hours at 20 ° C. The pellet is rinsed with absolute ethanol, centrifuged at 13,000 RPM, 4 ° C, 10 minutes and dissolved in 100 ⁇ l of distilled water.
- RNA harvested from biopsies is estimated by the optical density of the solution at 260 nm and then measured by amplifying the 28S ribosomal RNA by RT-PCR.
- the measurement of specific mRNAs is carried out by quantitative RT-PCR on aliquots of the same dilution of total RNA, stored at -80 ° C. until their use.
- the specific oligonucleotide primers of the genes studied have 24 bases, have an A - T% close to 50% and are chosen from two different exons in order to avoid amplification of possible traces of DNA present in the samples.
- the optimal amplification conditions (temperature and number of cycles) were determined for each of the genes studied, taking into account their level of expression in the skin.
- RT-PCR is made using the Gen amp Amp rTth kit from Perkin Elmer or the Titam kit from Boehringer.
- Each RT-PCR reaction is carried out in the presence of a known number of copies of a synthetic RNA created in the laboratory containing the sequences of the oligonucleotide primers specific for the mRNAs of interest and the amplification product of which has a molecular size allowing discriminate it from endogenous mRNA.
- This multistandard makes it possible to control and calculate the yield of the reverse transcription and of the amplification reaction.
- the amplification products are analyzed by electrophoresis in polyacrylamide gel followed by staining with CyberGreen.
- the intensity of the fluorescent signals is measured using a Fluoro S Multilmager.
- the results are corrected for the yield of RT-PCR and expressed in arbitrary units per unit of 28 S ribosomal RNA.
- the total quantity of RNA purified from biopsies is first evaluated by measuring the optical density at 260 nm and their quality estimated by measuring the OD ratio 260/290 nm.
- RNA was obtained from each of the biopsies (between 2.1 and 6.3 ⁇ g) with a satisfactory degree of purity (D.O. report 260/280).
- the concentration of total RNA is brought by dilution to a calculated value of 4 nanograms per ⁇ l. This process makes it possible to carry out the reverse transcription and amplification reactions on similar quantities of total RNA for all the samples.
- the amount of total RNA present in the diluted solution is quantitatively determined by measurement of the 28S ribosomal RNA, carried out in triplicate.
- RNA solution will be used for all measurements of specific RNAs, the results of which are expressed per unit of 28S RNA.
- C-PCP carboxyprocollagen peptidase
- N-PCP aminoprocollagen peptidase
- C-PCP N-PCP subject APA / PAPA / P a 108 65 1.66 298 224 1.33 b 170 139 1, 22 138 125 1, 10 c 155 152 1.02 271 312 0.87 d 274 188 1, 46 637 325 1.96 e 155 119 1.30 507 321 1.58 f 138 121 1, 14 254 213 1, 19 g 206 178 1, 16 349 350 1, 00 h 225 192 1.17 327 380 0.85 i 370 334 1, 11 409 517 0.79 j 212 159 1, 33 246 174 1, 41
- the 10 subjects of the study see the expression of increased C-PCP with ascorbic acid and six subjects out of 10 have an active / placebo ratio greater than 1 for N-PCP.
- the equilibrium rate of lysyloxidase mRNA is increased by ascorbic acid in 8 out of 10 subjects.
- the mean of the A / P ratios is significantly greater than 1 according to the unilateral Student T-test despite inter variability -individual more important than for the other enzymes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31727/00A AU3172700A (en) | 1999-03-24 | 2000-03-07 | Use of vitamin c or analogues for promoting transformation of inactive procollagen into active collagen |
EP00909443A EP1165062A1 (fr) | 1999-03-24 | 2000-03-07 | Utilisation de la vitamine c ou analogues pour promouvoir la transformation de procollagenes inactifs en collagenes actifs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/03674 | 1999-03-24 | ||
FR9903674A FR2791261A1 (fr) | 1999-03-24 | 1999-03-24 | Utilisation de la vitamine c ou analogue pour promouvoir la transformation de procollagenes inactifs en collagenes actifs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000056326A1 true WO2000056326A1 (fr) | 2000-09-28 |
Family
ID=9543583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000562 WO2000056326A1 (fr) | 1999-03-24 | 2000-03-07 | Utilisation de la vitamine c ou analogues pour promouvoir la transformation de procollagenes inactifs en collagenes actifs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1165062A1 (fr) |
AR (1) | AR018229A1 (fr) |
AU (1) | AU3172700A (fr) |
FR (1) | FR2791261A1 (fr) |
WO (1) | WO2000056326A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH072699A (ja) * | 1993-06-17 | 1995-01-06 | Kanebo Ltd | コラーゲン代謝賦活剤 |
WO1996019099A2 (fr) * | 1995-08-25 | 1996-06-27 | Lvmh Recherche | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
US5574063A (en) * | 1989-10-12 | 1996-11-12 | Perricone; Nicholas V. | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage |
JPH101414A (ja) * | 1996-06-12 | 1998-01-06 | Kanebo Ltd | 皮膚化粧料 |
-
1999
- 1999-03-24 FR FR9903674A patent/FR2791261A1/fr active Pending
-
2000
- 2000-03-07 EP EP00909443A patent/EP1165062A1/fr not_active Withdrawn
- 2000-03-07 AU AU31727/00A patent/AU3172700A/en not_active Abandoned
- 2000-03-07 WO PCT/FR2000/000562 patent/WO2000056326A1/fr not_active Application Discontinuation
- 2000-03-22 AR ARP000101264A patent/AR018229A1/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5574063A (en) * | 1989-10-12 | 1996-11-12 | Perricone; Nicholas V. | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage |
JPH072699A (ja) * | 1993-06-17 | 1995-01-06 | Kanebo Ltd | コラーゲン代謝賦活剤 |
WO1996019099A2 (fr) * | 1995-08-25 | 1996-06-27 | Lvmh Recherche | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
US5801192A (en) * | 1995-08-25 | 1998-09-01 | Lvmh Recherche | Use of vitamin C or derivatives or analogues thereof promoting skin elastin synthesis |
JPH101414A (ja) * | 1996-06-12 | 1998-01-06 | Kanebo Ltd | 皮膚化粧料 |
Non-Patent Citations (7)
Title |
---|
CHARLOTTE L. PHILIPS ET AL: "Effects of Acorbic Acid on Proliferation and Collagen Synthesis in Relation to the Donor Age of Human Dermal Fibroblasts", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 103, no. 2, August 1994 (1994-08-01), pages 228 - 232, XP000863260 * |
D. CHAN ET AL: "Regulation of procollagen synthesis and processing during ascorbate-induced extracellular matrix accumulation in vitro", THE BIOCHEMICAL JOURNAL, vol. 269, no. 1, 1 July 1990 (1990-07-01), pages 175 - 181, XP000863254 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GEESIN, JEFFREY C. ET AL: "Ascorbic acid specifically increases type I and type III procollagen messenger RNA levels in human skin fibroblasts", XP002125749, retrieved from STN Database accession no. 108:203655 HCA * |
DATABASE WPI Section Ch Week 199511, Derwent World Patents Index; Class B04, AN 1995-077968, XP002125015 * |
J. INVEST. DERMATOL. (1988), 90(4), 420-4 * |
N BOYERA ET AL: "Effect of vitamin C and its derivatives on collagen synthesis and cross-linking by normal human fibroblasts", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, vol. 20, 1998, pages 151 - 158, XP000863375 * |
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 05 30 April 1998 (1998-04-30) * |
Also Published As
Publication number | Publication date |
---|---|
AU3172700A (en) | 2000-10-09 |
EP1165062A1 (fr) | 2002-01-02 |
AR018229A1 (es) | 2001-10-31 |
FR2791261A1 (fr) | 2000-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1068864B1 (fr) | Utilisation d'au moins un hydroxystilbène comme agent anti-glycation. | |
EP1064931B1 (fr) | Composition cosmétique comprenant au moins un hydroxystilbene et de l'acide ascorbique | |
EP1090628B1 (fr) | Utilisation du lycopène dans des compositions destinées à traiter les signes cutanés du vieillissement | |
CA2328586A1 (fr) | Utilisation du 3,3',5,5'-tetrahydroxystilbene comme agent anti-glycation | |
FR2855968A1 (fr) | Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques | |
FR2802425A1 (fr) | Utilisation d'un extrait d'au moins un vegetal de la famille des ericaceae comme agent anti-glycation | |
CA2255229C (fr) | Utilisation de l'acide cinnamique ou de ses derives dans une composition cosmetique raffermissante | |
EP2346486B1 (fr) | Nouvel actif anti-vergetures et compositions le comprenant | |
FR2984742A1 (fr) | Utilisation de steviol, d'un derive glycoside du steviol, ou d'un de leurs isomeres, pour prevenir, reduire et/ou traiter une alteration du teint de la peau. | |
WO2020128223A1 (fr) | Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis | |
EP1146850A1 (fr) | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement | |
FR2812544A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal du genre salvia dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP1743628A1 (fr) | Composition cosmétique comprenant un extrait d'algue rouge comprenant une association de floridoside et d'acide iséthionique. | |
EP1430883A1 (fr) | Utilisation cosmétique de dérivés de l'acide ascorbique comme agents blanchissants de la peau ou des cheveux | |
WO2020115435A1 (fr) | Extrait de garcinia mangostana pour promouvoir la croissance capillaire | |
FR2905857A1 (fr) | Utilisation d'un extrait de pulpe de caroube pour hydrate la peau | |
FR2954702A1 (fr) | Agent stimulant l'expression de loxl | |
WO2000056278A1 (fr) | Utilisation de la vitamine c ou analogues pour stimuler la synthese de cellules de la peau | |
WO2022129775A1 (fr) | Utilisation cosmétique, nutraceutique ou dermatologique d'une souche de lactobacillus crispatus et/ou d'une composition la comprenant | |
WO2000056326A1 (fr) | Utilisation de la vitamine c ou analogues pour promouvoir la transformation de procollagenes inactifs en collagenes actifs | |
FR2977158A1 (fr) | Utilisation d'huile essentielle de bursera graveolens | |
WO2019077268A1 (fr) | Composition cosmétique de prévention active des signes de l'âge | |
FR3076461A1 (fr) | Composition cosmétique de prévention active des signes de l’âge. | |
EP3829626A1 (fr) | Extrait de lespedeza capitata pour son utilisation dans le domaine capillaire | |
WO2007066041A2 (fr) | Composition dépigmentante de la peau comprenant un dérivé d'acide naphtoique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000909443 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000909443 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000909443 Country of ref document: EP |